Anti CV2/CRMP5 antibody paraneoplastic syndrome: clinical features
Evidence-based neurology checklist on anti cv2/crmp5 antibody paraneoplastic syndrome: clinical features: Typical associated tumours Small cell lung cancer (SCLC) Thymoma Other associated tumours Encephalitic features Movement disorders Ophthalmic features Peripheral neuropathy (PN) Other clinical…
Typical associated tumours
- Small cell lung cancer (SCLC)
- Thymoma
Other associated tumours
Encephalitic features
Movement disorders
Ophthalmic features
Peripheral neuropathy (PN)
Other clinical features
Acronym
References
- De Beukelaar JW, Smitt PAS. Managing paraneoplastic neurological disorders. Oncologist 2006; 11:292-305.
- Graus F, Delattre JY, Antoine, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. JNNP 2004; 75:1235-1240.
- Helgason VÞ, Qureshi PAAA, Bollineni VR, Þórarinsson BL, Arkink EB. Anti-CV2/collapsin response mediator protein 5 (CRMP5) paraneoplastic encephalitis induced by small cell lung cancer. Cureus 2023; 15:e34323.
- Cross SA, Salomao DR, Parisi JE, et al. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol 2003; 54:38-50.
- Jarius S, Wandinger KP, Borowski K, Stoecker W, Wildemann B. Antibodies to CV2/CRMP5 in neuromyelitis optica-like disease: case report and review of the literature. Clin Neurol Neurosurg 2012; 114:331-335.
- And 22 more. Subscribe to see the full list
